{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-077111","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2024-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.323946+00:00","generated_at":"2026-05-31T05:37:31.022552+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Silo Pharma posts investor presentation for Sep 2024 conference; notes SPC-15 pre-IND submitted","bullets":["Presentation used at H.C. Wainwright 26th Annual Global Investment Conference on Sep 10, 2024.","Lead asset SPC-15 (intranasal PTSD treatment) pre-IND submitted for first-in-human trials.","Pipeline also includes SP-26 (ketamine implant for fibromyalgia), SPC-14 (Alzheimer's), SPU-16 (MS).","Exclusive licenses from Columbia University (SPC-15, SPC-14) and University of Maryland (SPU-16).","Company intends to use 505(b)(2) regulatory pathway for SPC-15 and SP-26 to shorten timelines."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-077111","json":"https://secwatch.observer/filing/0001213900-24-077111.json","markdown":"https://secwatch.observer/filing/0001213900-24-077111.md","text":"https://secwatch.observer/filing/0001213900-24-077111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024077111/0001213900-24-077111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390024077111/ea0213917-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:37:31.022552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}